AXON: 44% Off Highs But Still Wildly Expensive

Compare those multiples to the S&P 500 median and the premium becomes clear. Axon needs to grow into a valuation that currently prices in near-flawless execution for years.

The headline numbers looked strong. Q4 2025 revenue hit $797 million, beating consensus of $755 million and growing 39% year-over-year. Adjusted EPS of $2.15 crushed the $0.89 estimate. Management raised 2026 guidance to 27-30% revenue growth and set a bold $6 billion revenue target for 2028.

Dig beneath the surface and the story changes. GAAP net income for Q4 was $3 million — three million, on $797 million in revenue. That's a 0.4% net margin. Full-year GAAP net income totaled $125 million, but operating cash flow came in at just $211 million, and free cash flow collapsed to $75 million from $330 million the prior year.

Revenue nearly doubled from 2022 to 2025 while free cash flow fell 58%. That divergence should concern anyone paying 534x trailing free cash flow for this stock.

Axon spent $634 million on stock-based compensation in fiscal 2025 — more than five times its free cash flow. SBC represented 22.8% of revenue, dwarfing the 5-8% typical for mature software companies and even exceeding the 15% threshold that raises eyebrows among institutional investors.

This isn't an accounting abstraction. Diluted share count has expanded to roughly 100 million shares for EPS calculation purposes, versus 80 million basic shares outstanding. Every adjusted earnings metric that excludes SBC is overstating the economics available to shareholders.

Q4's gross margin slipped to 57.9%, down from 60.1% in Q3 and 60.6% in Q1. Operating expenses consumed virtually all gross profit — SG&A alone hit $317 million in Q4, while R&D ran at $134 million. Axon is investing aggressively in its AI-powered software platform, which is the right strategic move, but investors are paying today's premium for tomorrow's potential margins.

Credit where due: Axon's software transformation is genuine. Annual recurring revenue grew 35% to $1.35 billion. Software revenue hit $343 million in Q4 alone, growing 40% year-over-year. The contracted backlog of $14.4 billion — up 43% — provides exceptional revenue visibility.

The company dominates law enforcement technology with body cameras, tasers, and its Evidence.com cloud platform. AI-powered features like Draft One (automated police report writing) are driving adoption and expanding average revenue per user. Government customers are sticky, and switching costs are high.

But growth and value are different questions. The $6 billion revenue target for 2028 implies roughly 30% compound annual growth. Even hitting that target, at today's $40 billion market cap you'd be paying 6.7x 2028 revenue — still a premium multiple for a company with sub-1% GAAP net margins.

Axon's customer base is overwhelmingly government. Federal, state, and local law enforcement agencies represent the core of its revenue. DOGE-driven budget cuts have already targeted $11.1 billion in Pentagon efficiencies, with the Navy absorbing $3.7 billion in reductions, the Army $3.2 billion, and Air Force and Space Force $2.3 billion.

Axon isn't a traditional defense contractor, but it operates in the same funding ecosystem. Body camera mandates and cloud platform contracts flow through government procurement budgets. Any broad-based government austerity — whether from DOGE, continuing resolution constraints, or state-level fiscal pressure — directly impacts Axon's addressable market.

The 43% backlog growth provides some insulation, since contracted revenue is harder to claw back than discretionary spending. But new contract awards could slow if procurement offices tighten. Insider selling from CEO Rick Smith (0.32% stake reduction) and Chief Accounting Officer Jennifer Mak (10.92% of holdings) doesn't inspire confidence that management sees the current risk-reward favorably.